Eli Lilly and Co at Barclays Global Healthcare Conference Transcript

Mar 13, 2019 / 12:30PM GMT
Geoffrey Christopher Meacham - Barclays Bank PLC, Research Division - MD & Senior Research Analyst

All right. Good morning, and welcome to the second day of the Barclays Global Health Care Conference. My name's Geoff Meacham. I'm the Biopharma Analyst here. I've Olivia Brayer from my team on stage with me as well.

And it's our the pleasure to have Eli Lilly up here on stage for a fireside chat. And we have Chief Scientific Officer Dan Skovronsky. Dan, welcome.

Daniel M. Skovronsky - Eli Lilly and Company - Senior VP & Chief Scientific Officer

Yes. Good morning, Geoff. Thanks for having us here.

Questions and Answers:

Geoffrey Christopher Meacham - Barclays Bank PLC, Research Division - MD & Senior Research Analyst

Yes. So the conversations typically on Lilly, I wanted to ask you, it's -- tend to focus on diabetes, and that's probably the most topical. So I guess the first question is, give us a sense for the successes that Trulicity has had commercially. And then maybe what is your kind of
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot